{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T05:09:42Z","timestamp":1792645782724,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,10,17]],"date-time":"2016-10-17T00:00:00Z","timestamp":1476662400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,10,17]],"date-time":"2016-10-17T00:00:00Z","timestamp":1476662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The insect-transmitted protozoan parasite\n                    <jats:italic>Trypanosoma cruzi<\/jats:italic>\n                    is the causative agent of Chagas disease, and infects 5\u20138 million people in Latin America. Chagas disease is characterised by an acute phase, which is partially resolved by the immune system, but then develops as a chronic life-long infection. There is a consensus that the front-line drugs benznidazole and nifurtimox are more effective against the acute stage in both clinical and experimental settings. However, confirmative studies have been restricted by difficulties in demonstrating sterile parasitological cure. Here, we describe a systematic study of nitroheterocyclic drug efficacy using highly sensitive bioluminescence imaging of murine infections. Unexpectedly, we find both drugs are more effective at curing chronic infections, judged by treatment duration and therapeutic dose. This was not associated with factors that differentially influence plasma drug concentrations in the two disease stages. We also observed that fexinidazole and fexinidazole sulfone are more effective than benznidazole and nifurtimox as curative treatments, particularly for acute stage infections, most likely as a result of the higher and more prolonged exposure of the sulfone derivative. If these findings are translatable to human patients, they will have important implications for treatment strategies.\n                  <\/jats:p>","DOI":"10.1038\/srep35351","type":"journal-article","created":{"date-parts":[[2016,10,17]],"date-time":"2016-10-17T07:10:17Z","timestamp":1476688217000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":85,"title":["Nitroheterocyclic drugs cure experimental Trypanosoma cruzi infections more effectively in the chronic stage than in the acute stage"],"prefix":"10.1038","volume":"6","author":[{"given":"Amanda Fortes","family":"Francisco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiromani","family":"Jayawardhana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen L.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Shackleford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Osuna-Cabello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin D.","family":"Read","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan A.","family":"Charman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Chatelain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,17]]},"reference":[{"key":"BFsrep35351_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/B978-0-12-385863-4.00001-0","volume":"75","author":"LV Kirchhoff","year":"2011","unstructured":"Kirchhoff, L. V. Epidemiology of American trypanosomiasis (Chagas disease). Adv. Parasitol. 75, 1\u201315 (2011).","journal-title":"Adv. Parasitol."},{"key":"BFsrep35351_CR2","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1086\/605091","volume":"49","author":"C Bern","year":"2009","unstructured":"Bern, C. & Montgomery, S. P. An estimate of the burden of Chagas disease in the UnitedStates. Clin. Infect. Dis. 49, e52\u2013e54 (2009).","journal-title":"Clin. Infect. Dis."},{"key":"BFsrep35351_CR3","unstructured":"www.who.int\/neglected_diseases\/integrated_media_chagas_statement\/en\/index."},{"key":"BFsrep35351_CR4","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1586\/erc.10.33","volume":"8","author":"FJ Carod-Artal","year":"2010","unstructured":"Carod-Artal, F. J. Trypanosomiasis, cardiomyopathy and the risk of ischemic stroke. Expert Rev. Cardiovasc. Ther. 8, 717\u2013728 (2010).","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"BFsrep35351_CR5","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00418-014-1250-x","volume":"42","author":"S Jabari","year":"2014","unstructured":"Jabari, S., de Oliveira, E. C., Brehmer, A. & da Silveira, A. B. Chagasic megacolon: entericneurons and related structures. Histochem. Cell. Biol. 42, 235\u2013244 (2014).","journal-title":"Histochem. Cell. Biol."},{"key":"BFsrep35351_CR6","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1002\/jps.23010","volume":"101","author":"CJ Salomon","year":"2012","unstructured":"Salomon, C. J. First century of Chagas\u2019 disease: an overview on novel approaches to nifurtimox and benzonidazole delivery systems. J. Pharm. Sci. 101, 888\u2013894 (2012).","journal-title":"J. Pharm. Sci."},{"key":"BFsrep35351_CR7","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.2174\/0929867322666151015120804","volume":"22","author":"L Gaspar","year":"2015","unstructured":"Gaspar, L. et al. Current and future chemotherapy for Chagas disease. Curr. Med. Chem. 22, 4293\u20134312 (2015).","journal-title":"Curr. Med. Chem."},{"key":"BFsrep35351_CR8","doi-asserted-by":"publisher","first-page":"5022","DOI":"10.1073\/pnas.0711014105","volume":"105","author":"SR Wilkinson","year":"2008","unstructured":"Wilkinson, S. R., Taylor, M. C., Horn, D., Kelly, J. M. & Cheeseman, I. A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proc. Natl. Acad. Sci. USA 105, 5022\u20135027 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFsrep35351_CR9","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1093\/infdis\/jis331","volume":"206","author":"AM Mejia","year":"2012","unstructured":"Mejia, A. M. et al. Benznidazole-resistance in Trypanosoma cruzi is a readily acquired trait that can arise independently in a single population. J. Inf. Dis. 206, 220\u2013228 (2012).","journal-title":"J. Inf. Dis."},{"key":"BFsrep35351_CR10","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1056\/NEJMoa1313122","volume":"370","author":"I Molina","year":"2014","unstructured":"Molina, I. et al. Randomized trial of posaconazole and benznidazole for chronic Chagas disease. N. Engl. J. Med. 370, 1899\u20131908 (2014).","journal-title":"N. Engl. J. Med."},{"key":"BFsrep35351_CR11","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1056\/NEJMoa1507574","volume":"373","author":"CA Morillo","year":"2015","unstructured":"Morillo, C. A. et al. Randomized trial of benznidazole for chronic Chagas\u2019 cardiomyopathy. N. Engl. J. Med. 373, 1295\u20131306 (2015).","journal-title":"N. Engl. J. Med."},{"key":"BFsrep35351_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1590\/S0074-02762002000100001","volume":"97","author":"J Rodriques Coura","year":"2002","unstructured":"Rodriques Coura, J. & de Castro, S. L. A critical review on Chagas disease chemotherapy. Mem. Inst. Oswaldo Cruz 97, 3\u201324 (2002).","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"BFsrep35351_CR13","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.pt.2005.08.026","volume":"21","author":"SL Croft","year":"2005","unstructured":"Croft, S. L., Barrett, M. P. & Urbina, J. A. Chemotherapy of trypanosomiases and leishmaniasis. Trends Parasitol. 21, 508\u2013512 (2005).","journal-title":"Trends Parasitol."},{"key":"BFsrep35351_CR14","doi-asserted-by":"publisher","first-page":"e31 pp1","DOI":"10.1017\/S1462399409001252","volume":"11","author":"SR Wilkinson","year":"2009","unstructured":"Wilkinson, S. R. & Kelly, J. M. Trypanocidal drugs: mechanisms, resistance and new targets. Expert Rev. Molec. Med. 11, e31 pp1\u201324 (2009).","journal-title":"Expert Rev. Molec. Med."},{"key":"BFsrep35351_CR15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.actatropica.2009.10.023","volume":"115","author":"JA Urbina","year":"2010","unstructured":"Urbina, J. A. Specific chemotherapy of Chagas disease: Relevance, current limitations and new approaches. Acta Trop. 115, 55\u201368 (2010).","journal-title":"Acta Trop."},{"key":"BFsrep35351_CR16","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/S1473-3099(10)70098-0","volume":"10","author":"A Rassi Jr.","year":"2010","unstructured":"Rassi, A. Jr., Rassi, A. & Marin-Neto, J. A. Chagas disease. Lancet Infect. Dis. 10, 556\u2013570 (2010).","journal-title":"Lancet Infect. Dis."},{"key":"BFsrep35351_CR17","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1086\/656917","volume":"51","author":"Y Jackson","year":"2010","unstructured":"Jackson, Y. et al. Tolerance and safety of nifurtimox in patients with chronic chagas disease. Clin. Infect. Dis. 51, e69\u2013e75 (2010).","journal-title":"Clin. Infect. Dis."},{"key":"BFsrep35351_CR18","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.2174\/156802611796575894","volume":"11","author":"SR Wilkinson","year":"2011","unstructured":"Wilkinson, S. R., Bot, C., Kelly, J. M. & Hall, B. S. Trypanocidal activity of nitroaromatic prodrugs: current treatments and future perspectives. Curr. Topics Med. Chem. 11, 2072\u20132084 (2011).","journal-title":"Curr. Topics Med. Chem."},{"key":"BFsrep35351_CR19","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1586\/eri.11.31","volume":"9","author":"PM Guedes","year":"2011","unstructured":"Guedes, P. M., Silva, G. K., Gutierrez, F. R. & Silva, J. S. Current status of Chagas disease chemotherapy. Expert Rev. Anti-infect. Ther. 9, 609\u2013620 (2011).","journal-title":"Expert Rev. Anti-infect. Ther."},{"key":"BFsrep35351_CR20","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1056\/NEJMct1014204","volume":"364","author":"C Bern","year":"2011","unstructured":"Bern, C. Antitrypanosomal therapy for chronic Chagas\u2019 disease. N. Engl. J. Med. 364, 2527\u20132534 (2011)","journal-title":"N. Engl. J. Med."},{"key":"BFsrep35351_CR21","first-page":"1","volume":"30","author":"J Bermudez","year":"2015","unstructured":"Bermudez, J., Davies, C., Simonazzi, A., Pablo Real, J. & Palma S. Current drug therapy and pharmaceutical challenges for Chagas disease. Acta Trop. 30, 1\u201316 (2015).","journal-title":"Acta Trop."},{"key":"BFsrep35351_CR22","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.ab.2009.09.009","volume":"396","author":"BR Branchini","year":"2010","unstructured":"Branchini, B. R. et al. Red-emitting luciferases for bioluminescence reporter and imaging applications. Anal. Biochem. 396, 290\u2013297 (2010).","journal-title":"Anal. Biochem."},{"key":"BFsrep35351_CR23","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1111\/cmi.12297","volume":"16","author":"MD Lewis","year":"2014","unstructured":"Lewis, M. D. et al. Bioluminescence imaging of chronic Trypanosoma cruzi infections reveals tissue-specific parasite dynamics and heart disease in the absence of locally persistent infection. Cell. Microbiol. 16, 1285\u20131300 (2014).","journal-title":"Cell. Microbiol."},{"key":"BFsrep35351_CR24","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1177\/1087057114552623","volume":"20","author":"MD Lewis","year":"2015","unstructured":"Lewis, M. D., Fortes Francisco, A., Taylor, M. C. & Kelly, J. M. A new experimental model for assessing drug efficacy against Trypanosoma cruzi infection based on highly sensitive in vivo imaging. J. Biomolec. Screening 20, 36\u201343 (2015).","journal-title":"J. Biomolec. Screening"},{"key":"BFsrep35351_CR25","doi-asserted-by":"publisher","first-page":"4653","DOI":"10.1128\/AAC.00520-15","volume":"59","author":"A Fortes Francisco","year":"2015","unstructured":"Fortes Francisco, A. et al. The limited ability of posaconazole to cure both acute and chronic Trypanosoma cruzi infections revealed by highly sensitive in vivo imaging. Antimicrob. Agents Chemother. 59, 4653\u20134661 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep35351_CR26","doi-asserted-by":"publisher","first-page":"e1870","DOI":"10.1371\/journal.pntd.0001870","volume":"6","author":"MT Bahia","year":"2012","unstructured":"Bahia, M. T. et al. Fexinidazole: a potential new drug candidate for Chagas disease. PLoS Negl. Trop. Dis. 6, e1870 (2012).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"BFsrep35351_CR27","doi-asserted-by":"publisher","first-page":"4362","DOI":"10.1128\/AAC.02754-13","volume":"58","author":"MT Bahia","year":"2014","unstructured":"Bahia, M. T. et al. Antitrypanosomal activity of fexinidazole metabolites, potential new drug candidates for Chagas disease. Antimicrob. Agents Chemother. 58, 4362\u20134370 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep35351_CR28","doi-asserted-by":"publisher","first-page":"e1363","DOI":"10.1371\/journal.pntd.0001363","volume":"5","author":"MD Lewis","year":"2011","unstructured":"Lewis, M. D. et al. Recent, independent and anthropogenic origins of Trypanosoma cruzi hybrids. PLoS Negl. Trop. Dis. 5, e1363 (2011).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"BFsrep35351_CR29","doi-asserted-by":"crossref","unstructured":"Lewis, M. D., Fortes Francisco, A., Taylor, M. C., Jayawardhana, S. & Kelly, J. M. Host and parasite genetics shape a link betweensTrypanosoma cruzi infection dynamics and chronic cardiomyopashs. Cell. Microbiol. 18, 1429\u20131443 (2016).","DOI":"10.1111\/cmi.12584"},{"key":"BFsrep35351_CR30","doi-asserted-by":"publisher","first-page":"e923","DOI":"10.1371\/journal.pntd.0000923","volume":"4","author":"E Torreele","year":"2010","unstructured":"Torreele, E. et al. Fexinidazole \u2013 a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl. Trop. Dis. 4, e923 (2010).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"BFsrep35351_CR31","doi-asserted-by":"publisher","first-page":"4807","DOI":"10.2147\/DDDT.S90208","volume":"9","author":"E Chatelain","year":"2015","unstructured":"Chatelain, E. & Konar, N. Translational challenges of animal models in Chagas disease drug development: a review. J. Drug Des. Devel. Ther. 9, 4807\u20134823 (2015).","journal-title":"J. Drug Des. Devel. Ther."},{"key":"BFsrep35351_CR32","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/B978-0-12-385863-4.00005-8","volume":"75","author":"F Buckner","year":"2011","unstructured":"Buckner, F. Experimental chemotherapy and approaches to drug discovery for Trypanosoma cruzi infection. Adv. Parasitol. 75, 89\u2013119 (2011).","journal-title":"Adv. Parasitol."},{"key":"BFsrep35351_CR33","doi-asserted-by":"publisher","first-page":"e740","DOI":"10.1371\/journal.pntd.0000740","volume":"4","author":"AM Canavaci","year":"2010","unstructured":"Canavaci, A. M. et al. In vitro and in vivo high-throughput assays for the testing of anti-Trypanosoma cruzi compounds. PLoS Negl. Trop. Dis. 4, e740 (2010).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"BFsrep35351_CR34","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1590\/S0074-02762010000200022","volume":"105","author":"AJ Romanha","year":"2010","unstructured":"Romanha, A. J. et al. In vitro and in vivo experimental models for drug screening and development for Chagas disease. Mem. Inst. Oswaldo Cruz 105, 233\u2013238 (2010).","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"BFsrep35351_CR35","unstructured":"http:\/\/www.dndi.org\/diseases-projects\/chagas\/chagas-target-product-profile\/."},{"key":"BFsrep35351_CR36","doi-asserted-by":"publisher","first-page":"e0128707","DOI":"10.1371\/journal.pone.0128707","volume":"10","author":"T Ass\u00edria Fontes Martins","year":"2015","unstructured":"Ass\u00edria Fontes Martins, T. et al. Benznidazole\/itraconazole combination treatment enhances anti-Trypanosoma cruzi activity in experimental Chagas disease. PLoS One 10, e0128707 (2015).","journal-title":"PLoS One"},{"key":"BFsrep35351_CR37","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.4269\/ajtmh.13-0690","volume":"92","author":"AP Gruendling","year":"2015","unstructured":"Gruendling, A. P. et al. Impact of benznidazole on infection course in mice experimentally infected with Trypanosoma cruzi I, II, and IV. Am. J. Trop. Med. Hyg. 92, 1178\u20131189 (2015).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"BFsrep35351_CR38","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.actatropica.2013.03.006","volume":"127","author":"A Molina-Berr\u00edos","year":"2013","unstructured":"Molina-Berr\u00edos, A. et al. Benznidazole prevents endothelial damage in an experimental model of Chagas disease. Acta Trop. 127, 6\u201313 (2013).","journal-title":"Acta Trop."},{"key":"BFsrep35351_CR39","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1128\/AAC.01451-09","volume":"54","author":"C Davies","year":"2010","unstructured":"Davies, C. et al. Basombr\u00edo MA. Hydroxymethylnitrofurazone is active in a murine model of Chagas\u2019 disease. Antimicrob. Agents Chemother. 54, 3584\u20133589 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep35351_CR40","first-page":"CD003463","volume":"5","author":"JC Villar","year":"2014","unstructured":"Villar, J. C. et al. Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection. Cochrane Database Syst. Rev. 5, CD003463 (2014).","journal-title":"Cochrane Database Syst. Rev."},{"key":"BFsrep35351_CR41","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1056\/NEJMc1514453","volume":"374","author":"RL Hamers","year":"2016","unstructured":"Hamers, R. L., van Gool, T. & Goorhuis, A. Benznidazole for chronic Chagas\u2019 cardiomyopathy. N. Engl. J. Med. 374, 188 (2016).","journal-title":"N. Engl. J. Med."},{"key":"BFsrep35351_CR42","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1056\/NEJMc1514453","volume":"374","author":"MA Cordeiro","year":"2016","unstructured":"Cordeiro, M. A. Benznidazole for chronic Chagas\u2019 cardiomyopathy. N. Engl. J. Med. 374, 188\u2013189 (2016).","journal-title":"N. Engl. J. Med."},{"key":"BFsrep35351_CR43","first-page":"189","volume":"374","author":"JA Urbina","year":"2016","unstructured":"Urbina, J. A., Gascon, J. & Ribeiro, I. Benznidazole for chronic Chagas\u2019 cardiomyopathy. N. Engl. J. Med. 374, 189 (2016).","journal-title":"N. Engl. J. Med."},{"key":"BFsrep35351_CR44","first-page":"189","volume":"374","author":"CA Morillo","year":"2016","unstructured":"Morillo, C. A., Marin-Neto, J. A. & Avezum, A. Benznidazole for chronic Chagas\u2019 cardiomyopathy. N. Engl. J. Med. 374, 189\u2013190 (2016).","journal-title":"N. Engl. J. Med."},{"key":"BFsrep35351_CR45","unstructured":"http:\/\/www.dndi.org\/diseases-projects\/portfolio\/fexinidazole-chagas\/."},{"key":"BFsrep35351_CR46","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1128\/AAC.05135-11","volume":"56","author":"BS Hall","year":"2012","unstructured":"Hall, B. S. & Wilkinson, S. R. Activation of benznidazole by trypanosomal type I nitroreductases results in glyoxal formation. Antimicrob. Agents Chemother. 56, 115\u2013123 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep35351_CR47","doi-asserted-by":"publisher","first-page":"13088","DOI":"10.1074\/jbc.M111.230847","volume":"286","author":"BS Hall","year":"2011","unstructured":"Hall, B. S., Bot, C. & Wilkinson, S. R. Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites. J. Biol. Chem. 286, 13088\u201313095 (2011).","journal-title":"J. Biol. Chem."},{"key":"BFsrep35351_CR48","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/0014-4894(86)90039-1","volume":"62","author":"EL Isola","year":"1986","unstructured":"Isola, E. L., Lammel, E. M. & Gonzalez Cappa, S. M. Trypanosoma cruzi: differentiation after interaction of epimastigotes and Triatoma infestans intestinal homogenate. Exp. Parasitol. 62, 329\u2013335 (1986).","journal-title":"Exp. Parasitol."},{"key":"BFsrep35351_CR49","doi-asserted-by":"publisher","first-page":"5540","DOI":"10.1021\/jm200592f","volume":"54","author":"JM Coteron","year":"2011","unstructured":"Coteron, J. M. et al. Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential. J. Med. Chem. 54, 5540\u20136551 (2011).","journal-title":"J. Med. Chem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep35351.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep35351","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep35351.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T18:56:41Z","timestamp":1672858601000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep35351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,17]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,16]]}},"alternative-id":["BFsrep35351"],"URL":"https:\/\/doi.org\/10.1038\/srep35351","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,17]]},"assertion":[{"value":"4 August 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35351"}}